| 1.92 0.06 (3.23%) | 03-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.4 | 1-year : | 2.75 |
| Resists | First : | 2.05 | Second : | 2.35 |
| Pivot price | 2.02 |
|||
| Supports | First : | 1.58 | Second : | 1.31 |
| MAs | MA(5) : | 2 |
MA(20) : | 2.02 |
| MA(100) : | 2.15 |
MA(250) : | 3.19 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.8 |
D(3) : | 34.8 |
| RSI | RSI(14): 45.2 |
|||
| 52-week | High : | 10.17 | Low : | 1.58 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALZN ] has closed above bottom band by 22.3%. Bollinger Bands are 25.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.92 - 1.94 | 1.94 - 1.95 |
| Low: | 1.8 - 1.81 | 1.81 - 1.82 |
| Close: | 1.9 - 1.92 | 1.92 - 1.94 |
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Mon, 16 Mar 2026
New bipolar trial scans how lithium reaches the brain at Mass General - Stock Titan
Wed, 11 Mar 2026
Alzamend Neuro 10-Q: $0.00M Revenue, $(0.58) EPS Q3; $(1.89) EPS YTD - TradingView
Wed, 11 Mar 2026
Alzamend Neuro (NASDAQ: ALZN) posts $5.9M loss and warns on going concern - Stock Titan
Fri, 06 Mar 2026
Alzamend Neuro Launches $3 Million ATM Equity Program With Ascendiant Capital Markets - TradingView
Fri, 09 Jan 2026
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Wed, 19 Nov 2025
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 6.4 (%) |
| Shares Short | 263 (K) |
| Shares Short P.Month | 178 (K) |
| EPS | -2.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -72.8 % |
| Return on Equity (ttm) | -144.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.72 |
| PEG Ratio | 0 |
| Price to Book value | 1.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|